Acquired Company
Disc Medicine, Inc. completed its merger with Gemini Therapeutics, Inc. on December 29, 2022, and the combined company will operate under the name Disc Medicine, Inc. and its shares will commence trading on the Nasdaq Global Market under the ticker symbol IRON.
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies. Show more
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$59.76
Open
$60.54
Volume
384,381
Day Range
$59.00 - $62.54
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.25%
Institutional Own.
87.53%
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|